UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Tumor levels of the mediators of ErbB2-driven anoikis resistance correlate with breast cancer relapse in patients receiving trastuzumab-based therapies

Breast cancer research and treatment, 2021-06, Vol.187 (3), p.743-758

2021

Volltextzugriff (PDF)

Primary G-CSF prophylaxis for adjuvant TC or FEC-D chemotherapy outside of clinical trial settings: a systematic review and meta-analysis

Supportive care in cancer, 2012-10, Vol.20 (10), p.2523-2530

2012

Volltextzugriff (PDF)

Trastuzumab-induced upregulation of a protein set in extracellular vesicles emitted by ErbB2-positive breast cancer cells correlates with their trastuzumab sensitivity

Breast cancer research : BCR, 2020-10, Vol.22 (1), p.105-105, Article 105

2020

Volltextzugriff (PDF)

Nurse Navigators’ Views on Patient and System Factors Associated with Navigation Needs among Women with Breast Cancer

Current oncology (Toronto), 2021-06, Vol.28 (3), p.2107-2114

2021

Volltextzugriff (PDF)

Correction to: Trastuzumab-induced upregulation of a protein set in extracellular vesicles emitted by ErbB2-positive breast cancer cells correlates with their trastuzumab sensitivity

Breast cancer research : BCR, 2020-10, Vol.22 (1), p.1-110, Article 110

2020

Volltextzugriff (PDF)

ErbB2-driven downregulation of the transcription factor Irf6 in breast epithelial cells is required for their 3D growth

Breast cancer research : BCR, 2018-12, Vol.20 (1), p.151-151, Article 151

2018

Volltextzugriff (PDF)

Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations

Clinical Medicine Insights. Oncology, 2012-01, Vol.2012 (6), p.179-187

2012

Volltextzugriff (PDF)

The Cost-Utility of Sequential Adjuvant Trastuzumab in Women with Her2/Neu-Positive Breast Cancer: An Analysis Based On Updated Results from the HERA Trial

Value in health, 2009-07, Vol.12 (5), p.641-648

2009

Volltextzugriff (PDF)

Medical students' views on oncology specialty: A cross-sectional study

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.9038-9038

2024

Volltextzugriff (PDF)

The clinical utility of baseline cardiac assessments prior to adjuvant anthracycline chemotherapy in breast cancer: a systematic review and meta-analysis

Breast cancer research and treatment, 2019-04, Vol.174 (2), p.357-363

2019

Volltextzugriff (PDF)

The clinical utility of baseline cardiac assessments prior to adjuvant anthracycline chemotherapy in breast cancer: A systematic review and meta-analysis

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e12505-e12505

2018

Volltextzugriff (PDF)

Abstract PO3-17-10: Real-World evidence for Pembrolizumab-based neoadjuvant chemotherapy in early-stage triple negative breast cancer: a single institution experience

Cancer research (Chicago, Ill.), 2024-05, Vol.84 (9_Supplement), p.PO3-17-10-PO3-17-10

2024

Volltextzugriff (PDF)

Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer?

Supportive care in cancer, 2016-01, Vol.24 (1), p.387-394

2016

Volltextzugriff (PDF)

Oncology education for internal medicine residents: a call for action

Current oncology (Toronto), 2018-06, Vol.25 (3), p.189-190

2018

Volltextzugriff (PDF)

Should ASCO re-examine the febrile neutropenia threshold for primary G-CSF prophylaxis in breast cancer?

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e21671-e21671

2016

Volltextzugriff (PDF)

Impact of the 2013 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing of invasive breast carcinoma: a focus on tumours assessed as 'equivocal' for HER2 gene amplification by fluorescence in-situ hybridization

Histopathology, 2015-12, Vol.67 (6), p.880-887

2015

Volltextzugriff (PDF)

The impact of palliative care consultation on overall survival and aggressive care at the end-of-life in unresectable pancreatic cancer

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e18729-e18729

2018

Volltextzugriff (PDF)

Method of diagnosis of pancreatic adenocarcinoma: A Nova Scotia experience

Journal of clinical oncology, 2018-02, Vol.36 (4_suppl), p.252-252

2018

Volltextzugriff (PDF)

Palliative care intervention and aggressive care at end-of-life in patients with advanced pancreatic adenocarcinoma

Journal of clinical oncology, 2018-02, Vol.36 (4_suppl), p.244-244

2018

Volltextzugriff (PDF)

Timeliness of the oncology drug review process for public funding in Canada

Current oncology (Toronto), 2017-10, Vol.24 (5), p.279-281

2017

Volltextzugriff (PDF)

Isolated metastasis to the cerebellopontine angle secondary to breast cancer

Canadian journal of surgery, 2009-10, Vol.52 (5), p.E213-E214

2009

Volltextzugriff (PDF)

Adjuvant Trastuzumab for Breast Cancer: Uncertainties in Clinical and Economic Evidence Following Early Stopping of the HERA Trial

PharmacoEconomics, 2011-05, Vol.29 (5), p.361-365

2011

Volltextzugriff (PDF)

Adjuvant Trastuzumab for Breast Cancer

PharmacoEconomics, 2011-05, Vol.29 (5), p.361

2011

Volltextzugriff (PDF)

Implementing an exercise oncology model to reach rural and remote individuals living with and beyond cancer: a hybrid effectiveness-implementation protocol for project EXCEL (EXercise for Cancer to Enhance Living Well)

BMJ open, 2022-12, Vol.12 (12), p.e063953-e063953

2022

Volltextzugriff (PDF)

Adjuvant denosumab for breast cancer: What efficacy in the D-CARE trial will translate into cost effectiveness?

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.551-551

2014

Volltextzugriff (PDF)

1 – 25 von 60

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(60)
Mit Volltextzugriff
(53)

Publikationsform

Artikel
(60)

Sprache

Englisch
(60)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Tumor levels of the mediators of ErbB2-driven anoikis resistance correlate with breast cancer relapse in patients receiving trastuzumab-based therapies

Primary G-CSF prophylaxis for adjuvant TC or FEC-D chemotherapy outside of clinical trial settings: a systematic review and meta-analysis

Trastuzumab-induced upregulation of a protein set in extracellular vesicles emitted by ErbB2-positive breast cancer cells correlates with their trastuzumab sensitivity

Nurse Navigators’ Views on Patient and System Factors Associated with Navigation Needs among Women with Breast Cancer

Correction to: Trastuzumab-induced upregulation of a protein set in extracellular vesicles emitted by ErbB2-positive breast cancer cells correlates with their trastuzumab sensitivity

ErbB2-driven downregulation of the transcription factor Irf6 in breast epithelial cells is required for their 3D growth

Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations

The Cost-Utility of Sequential Adjuvant Trastuzumab in Women with Her2/Neu-Positive Breast Cancer: An Analysis Based On Updated Results from the HERA Trial

Medical students' views on oncology specialty: A cross-sectional study

The clinical utility of baseline cardiac assessments prior to adjuvant anthracycline chemotherapy in breast cancer: a systematic review and meta-analysis

The clinical utility of baseline cardiac assessments prior to adjuvant anthracycline chemotherapy in breast cancer: A systematic review and meta-analysis

Abstract PO3-17-10: Real-World evidence for Pembrolizumab-based neoadjuvant chemotherapy in early-stage triple negative breast cancer: a single institution experience

Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer?

Oncology education for internal medicine residents: a call for action

Should ASCO re-examine the febrile neutropenia threshold for primary G-CSF prophylaxis in breast cancer?

The impact of palliative care consultation on overall survival and aggressive care at the end-of-life in unresectable pancreatic cancer

Method of diagnosis of pancreatic adenocarcinoma: A Nova Scotia experience

Palliative care intervention and aggressive care at end-of-life in patients with advanced pancreatic adenocarcinoma

Timeliness of the oncology drug review process for public funding in Canada

Isolated metastasis to the cerebellopontine angle secondary to breast cancer

Adjuvant Trastuzumab for Breast Cancer: Uncertainties in Clinical and Economic Evidence Following Early Stopping of the HERA Trial

Adjuvant Trastuzumab for Breast Cancer

Implementing an exercise oncology model to reach rural and remote individuals living with and beyond cancer: a hybrid effectiveness-implementation protocol for project EXCEL (EXercise for Cancer to Enhance Living Well)

Adjuvant denosumab for breast cancer: What efficacy in the D-CARE trial will translate into cost effectiveness?

Suchergebnisse filtern